Altimmune's drug meets main goal of mid-stage study for alcohol use disorder
ALT•Mid-stage trial meets main goal
Altimmune ALT.O said on Tuesday its experimental drug met the main goal of a mid-stage trial for alcohol use disorder.
Related News
Ecolab Q2 Adjusted EPS USD 2.09 Vs. IBES Estimate USD 2.08
ECL•
Franklin Electric Q2 EPS USD 1.46
FELE•
Valmont Announces Planned Board Chair Transition
VMI•
Flow Traders selects CoreWeave as primary AI cloud provider for model training
CRWV•
Conagra eliminates COO role as Tom McGough retires in September 2026
CAG•